Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-2: LY2951742 for prevention of episodic migraine
2015-001882-17Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine and migraine comparing LY2951742 arm with Placebo arm (2 arms). Primary endpoint: Change in monthly migraine headache days. Started Nov 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
episodic migrainemigraine
Beyond the preview
Go deeper on 2015-001882-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001882-17.